Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer (ACCN)
Aromatase Inhibitors (AI) Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Treatment in Postmenopausal Hormone Receptor-positive Breast Cancer
Sponsor: Zhejiang Cancer Hospital
Listed as NCT02769104, this PHASE3 trial focuses on Neoadjuvant Therapy and remains ongoing. Sponsored by Zhejiang Cancer Hospital, it has been updated 6 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jun 2018 — Feb 2020 [monthly]
Recruiting PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Zhejiang Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .